Results 181 to 190 of about 164,918 (277)

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy‐Induced Cardiotoxicity

Advanced Science, EarlyView.
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo, Gayatri Mainkar, Matteo Ghiringhelli, Bernardo Gindri Dos Santos, Magdalena M. Żak, Keerat Kaur, Ann Anu Kurian, Matthew Adjmi, Segev Sharon, Eftychia Markopoulou, Lucia Žigová, Daniela Hirsch, Sydney Pessin, Rachel Hanan, Juan Luis Escano Abreu, Niki Brisnovali, Nicole Dubois, Leigh Goedeke, Mengcheng Shen, Lior Zangi   +19 more
wiley   +1 more source

Computational Development of Multi-Epitope Reovirus Vaccine with Potent Predicted Binding to TLR2 and TLR4. [PDF]

Pharmaceuticals (Basel)
Noman AA, Alhudhaibi AM, Sharma PD, Jannati SZ, Akhter T, Siddika S, Khan KF, Taha TH, Alsalamah SA, Abdallah EM.   +9 more
europepmc   +1 more source

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source

Tissue-Resident T Cells That Promote Humoral Immunity: Emerging From the Shadow of T Follicular Helper Cells. [PDF]

Immunol Rev
Chen S, Craft J.
europepmc   +1 more source

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

Advanced Science, EarlyView.
Cholangiocarcinoma (CCA) driven by oncogenic KRAS depends on its continuous activation for tumor maintenance. Using a conditional KRAS model, the authors show that turning off KRAS triggers rapid tumor regression accompanied by immune cell infiltration and cytokine release. The findings uncover a KRAS–senescence–immune signaling axis and highlight KRAS
Youwei Qiao, Matthew F. Yee, Chaitanya N. Parikh, Boyang Ma, Yueying Cao, Yu‐Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun‐Qing Liang, Wen Xue   +9 more
wiley   +1 more source

Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets. [PDF]

Brain Behav
Song S, Li B, Guo R, Zhou Y, Xue Y, Guo L.   +5 more
europepmc   +1 more source

Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset.

Journal of Clinical Investigation, 1986
C. Saltini, J. Spurzem, J. Lee, P. Pinkston, R. Crystal   +4 more
semanticscholar   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

The Role of Viral and Bacterial Infections in the Etiology of Behçet's Disease. [PDF]

J Clin Lab Anal
Moghoofei M, Pajavand H, Shahbazi R, Rezaei M, Taki E.   +4 more
europepmc   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

Advanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel, Anna Meurer, Badeel Kh. Q. Zaghla, Bilge Atay, Daniel Steiert, Luca V. Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse, Philipp Mertins, Stefan Müller, Matthias Wirth, Martin G. Klatt, Ulrich Keller   +19 more
wiley   +1 more source